Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PCSK9 Inhibitor Treatment for Patients With Hereditary Spastic Paraplegia Type 5

NCT04101643 is registered in ClinicalTrials.gov with First Affiliated Hospital of Fujian Medical University as lead sponsor.

NCT NCT04101643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04101643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PCSK9 Inhibitor Treatment for Patients With Hereditary Spastic Paraplegia Type 5
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 29, 2019
Completion date
January 3, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary spastic paraplegia type 5